Osteoporosis Anabolic Drugs Market Size, Share, and Industry Analysis, By Molecule Type (PTH Analogs, Sclerostin Inhibitors, Next-gen Anabolics, and Others), By Route of Administration (Injectable and Other Parenteral), By Patient Segment (Postmenopausal osteoporosis, Male osteoporosis, Glucocorticoid-induced osteoporosis, and High-fracture-risk / severe osteoporosis), By Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies, and Online), and Regional Forecast 2026-2034

The osteoporosis anabolic drugs market was valued at USD 3.50 billion in 2025. The market is projected to grow from USD 3.81 billion in 2026 to USD 7.50 billion by 2034, exhibiting a CAGR of 8.8% during the forecast period.

The global osteoporosis anabolic drugs market is a specialized segment of the broader osteoporosis therapeutics industry, focused on medicines that help build new bone in patients with severe osteoporosis or very high fracture risk. The market is gaining traction due to the growing geriatric population, rising fragility fracture burden, and stronger clinical focus on early intervention in high-risk patients, which is increasing demand for advanced bone-forming therapies. Additionally, the market remains commercially concentrated, with growth largely shaped by branded anabolic products, geographic expansion strategies, and company efforts to strengthen access through partnerships, licensing deals, and portfolio transactions.

• For instance, in March 2026, Paratek Pharmaceuticals, Inc., completed its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines. Such strategic collaborations boost market growth.

Furthermore, funding initiatives, strategic collaboration and partnerships, research and development, and new product launches by major companies strengthen their market position and support the overall market growth.

Osteoporosis Anabolic Drugs Market Driver

Growing Aging Population and Increasing High-Risk Patient Pool Driving Osteoporosis Anabolic Drugs Market Growth

The steady growth in the elderly population is driving the global osteoporosis anabolic drugs market. As people age, bone loss, fracture susceptibility, and the number of patients classified as high risk or very high-risk increase. These factors result in a higher demand for osteoporosis anabolic drugs market. As more people live longer, healthcare systems are seeing a larger pool of patients who need stronger bone-building therapies. This is increasing physician focus on anabolic drugs for patients with severe osteoporosis, multiple prior fractures, or imminent fracture risk. These factors are supporting demand for premium anabolic therapies in osteoporosis care.

• For instance, in February 2025, the WHO reported that by 2030, 1 in 6 people globally will be aged 60 years or over. WHO reported that the number of people aged 60+ will rise from 1.1 billion in 2023 to 1.4 billion by 2030.

Download Free sample to learn more about this report.

For instance, in 2019, there were 703 million people aged 65 or older, a number projected to reach 1.5 billion by 2050. According to the latest population estimates and projections from UN DESA's Population Division, 1 in 6 people worldwide will be over 65 by 2050, up from 1 in 11 in 2019.

Osteoporosis Anabolic Drugs Market Restraint

Safety Concerns Associated with Certain Anabolic Therapies to Limit Market Growth

The growth of the global osteoporosis anabolic drugs market is restrained by safety concerns linked to some advanced bone-forming therapies. These concerns make physicians more selective in prescribing and can slow broader adoption. When a therapy carries cardiovascular warnings such as myocardial infarction, stroke, and cardiovascular death or requires closer patient screening, its use is often limited to a narrower group of high-risk patients who are considered suitable after benefit-risk evaluation. These factors reduce prescribing confidence in routine practice and can delay treatment decisions, especially in elderly patients who already have multiple comorbidities.

• For instance, in December 2023, Australia's Therapeutic Goods Administration issued a safety update stating that stronger warnings were needed for romosozumab cardiovascular risks and that its use became contraindicated in patients with a history of myocardial infarction or stroke. Such factors highlight how safety-related regulatory actions can act as a restraint on market growth.

Osteoporosis Anabolic Drugs Market Opportunity

Growing Development of Next-Generation Bone-Forming Therapies Creating Significant Market Expansion Opportunities

The global osteoporosis anabolic drugs market has significant growth opportunities in the development of next-generation bone-forming therapies, as these products are helping move treatment beyond traditional osteoporosis management toward more targeted and effective fracture prevention. As newer anabolic agents demonstrate greater clinical value, better positioning for high-risk patients, and broader use across patient groups, companies gain more room to expand prescribing adoption and geographic reach. This creates an opportunity for the market to grow not only through new product innovation but also through lifecycle expansion, wider commercialization, and improved physician confidence in advanced bone-building treatment options. In effect, continued development of newer bone-forming therapies is widening the future commercial potential of the osteoporosis anabolic drug market.

• For instance, in January 2025, Radius Pharmaceuticals announced a licensing agreement with Pharmanovia to register and commercialize abaloparatide, described by the company as a novel bone-forming agent, in China and select Asia Pacific territories. These developments highlight how continued development and expansion of newer anabolic therapies are creating new market opportunities in underpenetrated regions and supporting future revenue growth.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Osteoporosis, By Key Countries/Region, 2025
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Regulatory & Reimbursement Scenarios, By Key Countries/Regions

Analysis by Molecule Type

Based on molecule type, the global osteoporosis anabolic drugs market is segmented into PTH analogs, sclerostin inhibitors, next-gen anabolics, and others.

The PTH analogs segment is estimated to hold a leading share. PTH analogs are likely to dominate the market, as they have had a longer commercial presence and a wider installed base of treatments. Also, broader treatment history and multiple branded and generic-linked commercial pathways have helped this segment maintain leadership. Underscoring these factors, key companies are focusing on research initiatives to develop new products and secure the regulatory approvals that follow, thereby strengthening growth.

• For instance, in December 2025, Amphastar Pharmaceuticals received approval from the U.S. FDA for teriparatide injection, with the FDA determining it is bioequivalent and therapeutically equivalent to Eli Lilly's Forteo. Such developments indicate continued commercial activity in the PTH analog class and reinforce its dominant market position.

Analysis by Route of Administration

Based on route of administration, the global osteoporosis anabolic drugs market is segmented into injectable and other parenteral.

Among these, the injectable segment is anticipated to hold a leading market share. Injectable subcutaneous administration is likely to dominate the market as currently marketed osteoporosis anabolic drugs are primarily designed and prescribed through this route. These therapies are used for patients with severe osteoporosis or very high fracture risk. Physicians generally prefer well-established injectable formats that have proven efficacy and defined dosing pathways. Also, increasing reimbursement initiatives and greater market access fuel their segmental growth. 

• For instance, in January 2025, Theramex received reimbursement from the National Health Service for Eladynos (Abaloparatide), a new injectable subcutaneous solution indicated for osteoporosis in postmenopausal women at increased risk of fracture.

Analysis by Patient Segment

Based on patient segment, the market is divided into postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and high-fracture-risk/severe osteoporosis.

Among these, postmenopausal osteoporosis is estimated to dominate the market. Women after menopause represent the largest diagnosed and treated osteoporosis patient pool globally. Estrogen decline after menopause directly accelerates bone loss and increases fracture risk, which creates a larger need for bone-building therapies in this segment. Many leading anabolic drugs were also first developed, studied, and commercialized in this population, which has strengthened prescribing confidence and access. As a result, the postmenopausal segment continues to generate the strongest demand and remains the core commercial focus for osteoporosis anabolic drug manufacturers.  

• For instance, in April 2025, UCB announced global real-world data on romosozumab for patients at high fracture risk, and the company noted that in the EU, the product is indicated for severe osteoporosis in postmenopausal women at high risk of fracture. Such developments show that postmenopausal women remain the primary commercial focus for major anabolic osteoporosis therapies.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, retail & specialty pharmacies, and online pharmacies.

Retail and specialty pharmacies are likely to dominate the market as osteoporosis anabolic drugs are prescribed for ongoing outpatient management rather than mainly for acute in-hospital use. Patients receiving these therapies usually continue treatment for weeks or months, making specialty and retail pharmacy channels more practical for refill access, patient support, and chronic therapy management. Additionally, companies are expanding commercial partnerships and specialty medicine platforms that are better aligned with specialty pharmacy distribution than hospital-only dispensing. As a result, retail and specialty pharmacies are likely to account for the largest share of product movement in this market.   

• For instance, in December 2024, Radius Pharmaceuticals expanded its abaloparatide licensing agreement with Theramex, granting additional commercialization rights for multiple countries, including Mexico, Canada, South Africa, Israel, and Russia. Such commercialization-led expansion supports wider outpatient product access and strengthens the role of retail and specialty pharmacy channels in market growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 45.0 % of the global osteoporosis anabolic drugs market in 2025. The market drives the strong growth in North America. The region is anticipated to grow, supported by a large diagnosed and treated osteoporosis population, stronger screening, greater specialist access, and higher use of premium therapies among high-fracture-risk patients. This creates steady demand for advanced bone-building drugs and supports continued commercial expansion. Emphasizing these factors, key companies are also advancing their offerings through strategic partnerships to launch new products and boost market growth.

• For instance, in March 2026, Entera Bio Ltd. completed the submission to the U.S. FDA of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the Company's Investigational New Drug (IND) 505(b)(2) submission, to evaluate EB613 (Oral PTH (1-34), teriparatide).

Europe is expected to grow at a significant CAGR during the forecast period. The region has a high osteoporosis and fragility-fracture burden, and clinical guidelines are increasingly pushing very-high-risk patients toward earlier anabolic use. Many high-risk patients may need first-line anabolic drug treatment, especially after multiple vertebral fractures. This is increasing clinical focus on bone-forming therapies and improving the region's growth outlook. Additionally, favorable government regulations and strategic partnerships expand distribution and access, reducing friction in options and boosting market growth.

• For example, in March 2023, Radius announced that Theramex entered into an exclusive licensing agreement to commercialize ELADYNOS in the European Economic Area and the U.K. The development supported regional launch and distribution expansion for abaloparatide.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The market is growing in the Asia Pacific due to rapid ageing, rising healthcare spending, and a large, underpenetrated osteoporosis treatment opportunity. The increasing proportion of ageing people is set to increase across every country and region included, which directly raises the future fracture-risk population and the need for stronger osteoporosis therapies. As awareness and access improve, anabolic drugs are expected to gain more traction across the region.

• For instance, in September 2025, Uni-Bio Science Group signed a strategic cooperation agreement with Kexing Biopharm, a Chinese company, to commercialize Bogutai (Teriparatide Injection), a recombinant human parathyroid hormone analog (PTH1–34), in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. Such developments are driving the region's growth.

Key Players covered

The global osteoporosis anabolic drugs market is consolidated, with a few players capturing significant market share. The report includes the profiles of the following key players.

• Amgen Inc. (U.S.)
• UCB S.A. (Belgium)
• Radius Health, Inc. (U.S.)
• Paratek Pharmaceuticals, Inc. (U.K.)
• Theramex (U.S.)
• Eli Lilly and Company (U.S.)
• Amphastar Pharmaceuticals, Inc. (U.S.)
• Alvogen (U.S.)
• Entera Bio Ltd (Israel)
• Astellas Pharma Inc. (Japan)

Key Industry Developments

• February 2026: MAIA Pharmaceuticals, Inc., collaborated with Asahi Kasei Pharma Corp., under which MAIA will advance Teribone (teriparatide) for the treatment of osteoporosis in the U.S.
• July 2025: Entera Bio Ltd. announced in a written response to a Type A meeting request that the U.S. FDA agreed to the NDA marketing application filing for EB613, an oral anabolic (bone-forming) tablet treatment. The application would be supported by a phase 3 study in women with postmenopausal osteoporosis, in which a change in total hip BMD is the primary endpoint and the incidence of new or worsening vertebral fractures is the key secondary endpoint. This marks a shift from previous placebo-controlled phase 3 studies of new osteoporosis drugs, which used fracture incidence as the primary endpoint.